KannaLife Sciences Announces Creation of South Park Pharmaceuticals


WEST HILLS, N.Y., Aug. 13, 2013 (GLOBE NEWSWIRE) — , Inc. (“KannaLife”) and Biotech Inc. (“Biotech”), 50/50 joint venture partners of Ventures, LLC announced today, the of Park , Inc. (“SPPI”), a pharmaceutical company established for the purpose of developing, testing, marketing and selling botanical medicaments, naturopathic compounds and phyto-medical products for health and wellness.

Jason Cranford, CEO of Biotech stated, “It is becoming apparent to 21st century Americans, that well rounded medical practice in the U.S. must include a firm understanding of “Traditional Medicine” (also known as “Alternative Medicine”), currently practiced by 80% of the global population. If it weren’t the case, the U.S. Food and Drug Administration (the “FDA”) would never have published “Guidance for Industry Botanical Products” in 2004.”

Dean Petkanas, CEO of KannaLife added, “Having witnessed the FDA’s openness towards the eligibility of Hemoxin, a phyto-medical compound to treat Sickle Cell Disease, and having granted orphan designation for the same, given today’s environment and technology, the viability and potential of cannabinoid and endocannabinoid based therapeutics should be well received. If nothing else, Dr. Sanjay Gupta’s documentary ‘Weed’ which aired on CNN on August 11, 2013, and the citing of the U.S. Patent 6630507 ‘Cannabinoids as Antioxidants and Neuroprotectants’
during his interview with CNN’s Wolf Blitzer should start to straighten out the badly distorted scientific record regarding cannabinoid therapy.”

South Park Pharmaceuticals intends on participating in the national initiative recently referred to as “bold and audacious”, by Francis Collins, MD Ph.D, director of National Institutes of Health (NIH). On April 2, 2013, this “bold and audacious” plan was revealed by President Obama, during a joint press conference with Dr. Collins. President Obama stated that the…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS